Improving the lives of patients today and tomorrow requires the government to maintain a careful balance between incentivizing innovation and promoting affordability. The current system of temporary exclusivity followed by robust competition, although not perfect, strikes the right balance. Violating this balance would undermine the incentive for innovations to the detriment of patients.
A left-leaning pressure group recently sent a letter to Health and Human Services Secretary Robert F. Kennedy Jr. asking his agency to rescind the patent rights earned by the developers of GLP-1 drugs. Some 12% of U.S. adults have taken these medications.
Rescinding the patents is a dangerous idea that would reduce our health and well-being.
GLP-1 medications benefit patients with various conditions. They have become a popular weight loss drug that suppresses people’s appetites and helps patients living with Type 2 diabetes better control their blood sugar levels. They reduce the risks of heart attacks and strokes and have the potential to help patients living with addiction and neurodegenerative diseases.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Don’t undermine the system that incentivized GLP-1 development
Wayne H Winegarden
Improving the lives of patients today and tomorrow requires the government to maintain a careful balance between incentivizing innovation and promoting affordability. The current system of temporary exclusivity followed by robust competition, although not perfect, strikes the right balance. Violating this balance would undermine the incentive for innovations to the detriment of patients.
A left-leaning pressure group recently sent a letter to Health and Human Services Secretary Robert F. Kennedy Jr. asking his agency to rescind the patent rights earned by the developers of GLP-1 drugs. Some 12% of U.S. adults have taken these medications.
Rescinding the patents is a dangerous idea that would reduce our health and well-being.
GLP-1 medications benefit patients with various conditions. They have become a popular weight loss drug that suppresses people’s appetites and helps patients living with Type 2 diabetes better control their blood sugar levels. They reduce the risks of heart attacks and strokes and have the potential to help patients living with addiction and neurodegenerative diseases.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.